Research programme: PAR-1 antagonists - MerckAlternative Names: Research programme: thrombin receptor antagonists - Schering-Plough; SCH 205831; SCH 602539
Latest Information Update: 18 Nov 2009
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Mechanism of Action PAR 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Thrombosis
Most Recent Events
- 02 Apr 2009 Preclinical development is ongoing in the US with the orally administered PAR-1 antagonists (237th American Chemical Society National Meeting (237th-ACS-2009))
- 29 Nov 2005 Preclinical trials in Thrombosis in USA (PO)